Abstract:Hypoxia-ischemia is the most common cause of neonatal encephalopathy (NE). In most cases, an intrapartum event is presumed to lead to perinatal hypoxia ischemia, but the exact pathogenesis, and therefore timing, are often not known. 1 In well-resourced settings, therapeutic hypothermia (TH) reduces death and major neurodevelopmental disability in infants with NE. 2 However, there is heterogeneity in outcomes, and major neurodevelopmental disability is still seen in about one third of survivors who are treated with therapeutic hypothermia. 3 The heterogeneity in response of NE to TH means alternative treatments are desperately sought. As such, many biomarkers have been studied as surrogate measures of long-term outcome, in order to expedite assessment of potential treatments. Moreover, an important goal is to personalize treatment for NE such that individuals who might benefit from a different approach to TH, might be detected early. It is also important to study biomarkers that can discriminate between which babies benefit from TH versus those who may be at higher risk of an adverse outcome. 4 In the study by O'Gorman Tuura et al., the authors have explored the link between perfusion and neurodevelopmental outcomes using arterial spine labeling (ASL) as a neuroimaging marker for outcome prediction. 5 ASL is a noninvasive magnetic resonance imaging (MRI) technique in which protons in blood and water are magnetically labeled and the signal generated by the endogenous labels are detected by subtracting MRI signals during alternating labeled and unlabeled acquisitions. The images demonstrate signal intensity proportional to the amount of perfusion in each voxel and a quantitative measurement of cerebral blood flow (CBF) can be calculated. 6 Previous authors have described patterns of CBF using ASL in NE. Wintermark et al. demonstrated initial hypoperfusion on day 1 followed by hyperperfusion at days 2–3. 7 A study by Tang et al. reported lower CBF values in neonates with NE at 0–24 h and 3–7 days with higher values in the 1–3 day-old group. 8 The mean age at MRI in O'Gorman Tuura's paper was 5 days (range 3–9 days), which means that any hyperperfusion identified may not represent the 'peak' perfusion phase, but rather the tail end of the more severe cases. The problem with that theory is that the cohort studied included infants with mild to moderate NE and the authors found a relationship between altered perfusion and outcome even in those children with mild to moderate impairment following NE.

Impact of persistent pulmonary hypertension on cerebral oxygenation in infants with neonatal encephalopathy

Persistent pulmonary hypertension and short-term neurological outcomes in infants with moderate to severe hypoxic ischemic encephalopathy

24 Persistent pulmonary hypertension and short-term neurological outcomes in infants with hypoxic ischemic encephalopathy undergoing therapeutic hypothermia

The Progress in the Treatment of Persistent Pulmonary Hypertension in Neonatal

Elevated cerebral perfusion in neonatal encephalopathy is associated with neurodevelopmental impairments

1704 Cerebral Oxygen Saturation and Extraction in Neonates with Persistent Pulmonary Hypertension During the First 72 Hours of Life

Prevalence of Pulmonary Hypertension During Therapeutic Hypothermia for Hypoxic Ischemic Encephalopathy and Evaluation of Short-Term Outcomes

Persistent pulmonary hypertension in neonates with perinatal asphyxia and therapeutic hypothermia: a frequent and perilous combination

In-hospital outcomes of neonates with hypoxic-ischemic encephalopathy receiving extracorporeal membrane oxygenation

pCO2 values in asphyxiated infants under therapeutic hypothermia after tailored respiratory management: a retrospective cohort study

Role of amplitude-integrated electroencephalography in neonates with cardiovascular compromise

1248 NEURODEVELOPMENTAL(ND) AND CARDIORESPIRATORY(CR) FOLLOWUP OF INFANTS WITH PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN (PPHN)

A comprehensive study of clinical biomarkers, use of inotropic medications and fluid resuscitation in newborns with persistent pulmonary hypertension

Cerebral rScO2 Measured by Near-Infrared Spectroscopy (NIRS) During Therapeutic Hypothermia in Neonates with Hypoxic-Ischemic Encephalopathy: A Systematic Review

[Application of extracorporeal membrane oxygenation in the treatment of persistent pulmonary hypertension of the newborn].

Risk factors and outcomes of persistent pulmonary hypertension of the newborn in neonatal intensive care unit of al-minya university hospital in Egypt

Therapeutic hypothermia in infants with hypoxic-ischemic encephalopathy and reversible persistent pulmonary hypertension: short-term hospital outcomes

Cerebral blood flow in neonatal encephalopathy: biomarker or potential target?

Pathophysiology of persistent pulmonary hypertension of the newborn: Impact of the perinatal environment

Persistent pulmonary hypertension of the newborn: Advances in diagnosis and treatment

Effect of hypoxic myocardial injury on neonatal cerebral hemodynamics and brain tissue oxygen saturation